Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor

Transarterial Chemoembolization Companies

ID: MRFR/HC/7092-HCR
125 Pages
Satyendra Maurya
Last Updated: February 16, 2025
Pioneers in interventional oncology, Transarterial Chemoembolization (TACE) companies specialize in combating liver cancer. Their expertise lies in developing and refining TACE techniques, offering targeted and minimally invasive solutions that combine chemotherapy and embolization to effectively treat hepatic tumors, providing hope to patients worldwide.
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Transarterial Chemoembolization Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)4.9%
2024 Market Size$ 11.96 Billion
2025 Market Size$ 12.55 Billion
2035 Market Size$ 20.24 Billion
Key Players
Boston Scientific
Bayer
Merit Medical Systems
Terumo Corporation
Cook Medical
Medtronic
Opportunities
  • Market Growth Projections
  • Increasing Geriatric Population
  • Rising Incidence of Liver Cancer

Top Industry Leaders in the Transarterial Chemoembolization Market

Transarterial Chemoembolization Key Companies
 
Latest Transarterial Chemoembolization Companies Update:

Boston Scientific Received FDA approval for the Embozap Plus Embolization Bead System in November 2023, offering a versatile option for TACE procedures.

Sirtex Medical Limited Released positive data from a clinical trial on their SIR-Spheres Yttrium-90 resin microspheres for HCC treatment, showing improved survival rates.

Baxter International Launched the Embolic Bead Kit with Microspheres in Asia Pacific, providing healthcare professionals with a comprehensive solution for TACE procedures.

Cook Medical Collaborated with Sirtex Medical to develop and distribute a new delivery system for Yttrium-90 radioembolization, aiming to improve procedure efficiency and patient outcomes.

Isofol Medical AB Received CE Mark approval for their Elucis Pro microcatheter platform in Europe, designed for precise microsphere delivery during TACE procedures.

List of Transarterial Chemoembolization Key companies in the market
  • Advaxis Inc.
  • Baxter
  • Bellicum Pharmaceuticals
  • Boston Scientific Corporation
  • Cook
  • Hikma Pharmaceuticals PLC
  • Isofol Medical AB
  • Nippon Kayaku Co.
  • Novartis
  • Pfizer
  • Sirtex SIR-Spheres Pty Ltd.
  • Spectrum Pharmaceuticals